ABEONA THERAPEUTICS INC. Increase (Decrease) in Other Current Liabilities
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Other Current Liabilities of -$85.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-03-17
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was -$23.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $0.00.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2025-06-30 was -$174.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for the quarter ending 2025-03-31 was $112.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2025 was -$85.00K, a 631.25% decline from fiscal 2024.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2024 was $16.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2023 was -$203.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in other current liabilities for fiscal 2022 was -$292.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$23.00K derived: sum of 2 quarters · filed 2026-03-17 | -$197.00K derived: sum of 3 quarters · filed 2026-03-17 | -$85.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$174.00K derived: sum of 2 quarters · filed 2025-11-12 | -$62.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$62.00K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $112.00K 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $16.00K 10-K · filed 2026-03-17 | |||
| 2023-12-31 | -$198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$204.00K derived: sum of 2 quarters · filed 2025-03-20 | -$204.00K derived: sum of 3 quarters · filed 2025-03-20 | -$203.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$6.00K derived: sum of 2 quarters · filed 2024-11-14 | -$5.00K 10-Q · filed 2024-11-14 | -$1.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.00K 10-Q · filed 2024-08-12 | $5.00K derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-15 | $5.00K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$292.00K 10-K · filed 2024-03-18 | ||
| 2022-09-30 | -$296.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |